Oncternal Therapeutics (NASDAQ:ONCT) Price Target Lowered to

Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) had its price target trimmed by Cantor Fitzgerald from $4.00 to $1.30 in a research report released on Tuesday, The Fly reports. The brokerage currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Oncternal Therapeutics’ FY2023 earnings at ($0.50) EPS. ONCT has been the […]

Related Keywords

San Diego , California , United States , Jamesb Breitmeyer , Davidf Hale , , Cantor Fitzgerald , Waypoint Capital Advisors , Oncternal Therapeutics Inc , Millennium Management , Oncternal Therapeutics Company Profile , Ci Private Wealth , Oncternal Therapeutics , Get Rating , Oncternal Therapeutic , Brookline Capital Management , Therapeutics Trading Down , Capital Advisors , Sigma Advisers , Two Sigma Investments , Sigma Investments , Oncternal Therapeutics Daily , Nasdaq Onct , Conct , Medical , Lower Price Target ,